Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Dianthus Therapeutics from “sell” to “hold”, adding to a generally bullish analyst backdrop for the stock.
• Multiple firms remain positive on DNTH, with 11 Buy ratings and 2 Strong Buy ratings overall and a consensus price target of $117.82.
• The company’s latest quarter beat expectations, posting EPS of -$0.85 versus estimates of -$1.07, while revenue of $0.46 million also came in above forecasts.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

A number of other equities analysts have also commented on the stock. Wolfe Research initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday, April 9th. They issued an "outperform" rating and a $98.00 price objective for the company. HC Wainwright raised their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a "buy" rating in a report on Monday, March 9th. TD Cowen reiterated a "buy" rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. William Blair reiterated an "outperform" rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Finally, Stifel Nicolaus set a $120.00 price target on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Dianthus Therapeutics presently has an average rating of "Buy" and a consensus price target of $117.82.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $86.84 on Friday. The stock has a market capitalization of $4.75 billion, a price-to-earnings ratio of -21.03 and a beta of 1.18. Dianthus Therapeutics has a 1-year low of $16.64 and a 1-year high of $96.50. The company has a 50 day moving average price of $81.01 and a 200 day moving average price of $56.30.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts expect that Dianthus Therapeutics will post -3.95 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Edward Carr sold 43,682 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $3,559,646.18. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Ryan Savitz sold 8,224 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $89.84, for a total value of $738,844.16. Following the sale, the executive vice president owned 8,224 shares in the company, valued at $738,844.16. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 323,021 shares of company stock worth $26,564,008. 3.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of the company. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter worth $32,000. Parkside Financial Bank & Trust increased its position in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company's stock valued at $37,000 after buying an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $40,000. Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics during the second quarter worth approximately $27,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $64,000. 47.53% of the stock is currently owned by institutional investors.

More Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Dianthus Therapeutics and set a $130 price target, suggesting meaningful upside from current levels.
• Positive Sentiment: The firm raised several earnings estimates for Dianthus Therapeutics, including FY2026 EPS to ($4.81) from ($6.21) and FY2027 EPS to ($5.49) from ($6.04), which may be viewed as improved outlook revisions.
• Neutral Sentiment: HC Wainwright also updated quarterly EPS forecasts for Q2 2026, Q3 2026, Q4 2026, and multiple 2027 quarters, but these remain negative EPS estimates as the company is still expected to be unprofitable.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.